SENS

Senseonics Holdings Inc

Add to Watchlist

Advanced Chart

0.492

+0.003(0.612%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.4997

Open

0.4913

VWAP

0.49

Vol

591.73K

Mkt Cap

388.98M

Low

0.483

Amount

290.44K

EV/EBITDA(TTM)

Total Shares

530.89M

359.70M

EV/OCF(TTM)

P/S(TTM)

13.57

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

14.97M

+80.39%

-0.018

-8.35%

8.68M

+103.55%

-0.020

-50%

6.02M

+23.78%

-0.020

-39.21%

Estimates Revision

The market is revising Upward the revenue expectations for Senseonics Holdings, Inc. (SENS) for FY2025, with the revenue forecasts being adjusted by 1.02% over the past three months. During the same period, the stock price has changed by -31.89%.

Revenue Estimates for FY2025

Revise Upward

+1.02%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-11.54%

In Past 3 Month

Stock Price

Go Down

-31.89%

In Past 3 Month

3 Analyst Rating

147.72% Upside

Wall Street analysts forecast SENS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SENS is 1.22 USD with a low forecast of 1.00 USD and a high forecast of 1.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

147.72% Upside

Current: 0.492

Low

1.00

Averages

1.22

High

1.40

147.72% Upside

Current: 0.492

Low

1.00

Averages

1.22

High

1.40

Lake Street

Ben Haynor

initiated

2025-07-17

Reason

Lake Street

Ben Haynor

Price Target

2025-07-17

initiated

Reason

Lake Street analyst Ben Haynor initiated coverage of Senseonics with a Buy rating and $1 price target. Senseonics pioneered implantable continuous glucose monitors and has now introduced the first and only implantable CGM, Eversense 365, the analyst tells investors. Senseonics has laid out a long-term user forecast which contemplates reaching 12,000 patients this year, 24,000 next year, and over 50,000 by 2027, notes the analyst, who argues that reaching the company's patient forecasts "does not seem to be a heavy lift."

TD Cowen

NULL -> Buy

initiated

$1.25

2025-07-15

Reason

TD Cowen

Price Target

$1.25

2025-07-15

initiated

NULL -> Buy

Reason

TD Cowen initiated coverage of Senseonics with a Buy rating and $1.25 price target. The firm says the company is positioned for accelerated growth following the U.S. launch of Eversense 365, its year-long implantable continuous glaucous monitoring device. Senseonics is gaining market share and its pipeline should further enhance its competitiveness, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

2025-07-08

Reason

H.C. Wainwright

Price Target

2025-07-08

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Senseonics to $1.40 from $1.10 and keeps a Buy rating on the shares following the company's analyst event. Senseonics presented plans to increase the number of Eversense patients from approximately 13,000 in 2025 to over 50,000 by 2027, the analyst tells investors in a research note. The firm says management believes the company could reach operational break even by the end of 2027.

H.C. Wainwright

Sean Lee

initiated

$1.10

2025-06-02

Reason

H.C. Wainwright

Sean Lee

Price Target

$1.10

2025-06-02

initiated

Reason

H.C. Wainwright analyst Sean Lee assumed coverage of Senseonics with a Buy rating and $1.10 price target. The company has the only 365-day continuous glucose monitoring system on the market, the analyst tells investors in a research note. The firm says Senseonics is believed to be the fourth largest provider of continuous glucose monitoring systems in the U.S. The company's flagship product is Eversense 365, which is the first and so far only approved CGM system that lasts for 12 months, compared to 7-15 days for traditional CGMs, contends H.C. Wainwright.

Mizuho

Anthony Petrone

Buy

Initiates

2025-04-10

Reason

Mizuho

Anthony Petrone

Price Target

2025-04-10

Initiates

Buy

Reason

Mizuho initiated coverage of Senseonics with an Outperform rating and $2 price target, citing positive survey data for continued continuous glucose monitoring category adoption along with "bullish physician feedback" for the company's flagship Eversense 365 adoption over the next several years. Physician checks point toward well over 100 basis points of total U.S. share gains for Eversense 365 over the next several years, the analyst tells investors.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-03-05

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-03-05

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Senseonics Holdings Inc (SENS.A) is -6.57, compared to its 5-year average forward P/E of -8.51. For a more detailed relative valuation and DCF analysis to assess Senseonics Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.51

Current PE

-6.57

Overvalued PE

-2.26

Undervalued PE

-14.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.67

Current EV/EBITDA

-6.69

Overvalued EV/EBITDA

-0.34

Undervalued EV/EBITDA

-9.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

29.57

Current PS

10.75

Overvalued PS

57.27

Undervalued PS

1.87

Financials

Annual

Quarterly

FY2025Q1

YoY :

+23.97%

6.26M

Total Revenue

FY2025Q1

YoY :

-26.02%

-13.49M

Operating Profit

FY2025Q1

YoY :

-24.46%

-14.26M

Net Income after Tax

FY2025Q1

YoY :

-33.33%

-0.02

EPS - Diluted

FY2025Q1

YoY :

-19.75%

-16.51M

Free Cash Flow

FY2025Q1

YoY :

+262.20%

24.05

Gross Profit Margin - %

FY2025Q1

YoY :

-18.95%

-247.61

FCF Margin - %

FY2025Q1

YoY :

-39.07%

-227.89

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

280.6K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1675.05% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

12.9M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

280.6K

USD

Months

0-12

0.0

USD

Months

SENS News & Events

Events Timeline

2025-05-16 (ET)

2025-05-16

06:07:27

Senseonics 100M share Spot Secondary priced at 50c

2025-05-15 (ET)

2025-05-15

16:07:30

Senseonics announces common stock offering, no amount given

2025-05-08 (ET)

2025-05-08

16:44:00

Senseonics backs FY25 revenue view $34M-$38M, consensus $35.54M

News

4.0

07-15Benzinga

TD Cowen Initiates Coverage On Senseonics Holdings with Buy Rating, Announces Price Target of $1.25

1.0

06-04Newsfilter

Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes

4.0

06-02Benzinga

HC Wainwright & Co. Assumes Senseonics Holdings at Buy, Announces Price Target of $1.1